Skip to main content
Helixmith Co., Ltd logo

Helixmith Co., Ltd — Investor Relations & Filings

Ticker · 084990 ISIN · KR7084990001 KO Manufacturing
Open in API
Filings indexed 508 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 084990

About Helixmith Co., Ltd

https://www.helixmith.com/

Helixmith is a biotechnology company specializing in the research and development of gene therapies. Established in 1996, the company focuses on creating innovative biopharmaceuticals for diseases with significant unmet medical needs. Its core activities revolve around an extensive pipeline of next-generation gene therapy products. The primary therapeutic areas of focus include neurological and cardiovascular disorders, such as peripheral artery disease and coronary artery disease. Helixmith manages a comprehensive range of capabilities, from discovery and preclinical studies to clinical development of its drug candidates.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company Helixmith Co., Ltd. (헬릭스미스) for the period ending September 30, 2021. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
투자판단관련주요경영사항(샤르코-마리-투스병 치료제(Engensis: VM202) 제1/2a상 임상시험 Topline data 발표)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Helixmith) submitted to the KRX (Korea Exchange). It details the 'Topline data' results of a Phase 1/2a clinical trial for a specific drug (Engensis: VM202). This type of disclosure, which reports significant business developments such as clinical trial outcomes, is classified as a 'Regulatory Filing' (RNS) in our system, as it serves as a formal announcement of material information to the market.
2021-11-08 Korean
전환가액의조정(제4회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (4th series) issued by Helixmith. It details the change in conversion price due to a decline in market price, the calculation methodology, and the resulting change in the number of convertible shares. This type of disclosure is a standard corporate action related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2021-11-01 Korean
전환가액의조정(제4회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by Helixmith. It details the change in conversion price, the number of shares, and the calculation methodology based on market price fluctuations. This falls under capital structure changes related to debt-to-equity instruments, which is best classified as a Capital/Financing Update (CAP).
2021-10-05 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제3회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Helixmith regarding the acquisition of convertible bonds before maturity (early redemption). It details the bond series, acquisition amount, acquisition date, and the reason for the transaction (early redemption request). This falls under capital structure changes and financing updates, specifically related to debt instruments.
2021-09-30 Korean
기타경영사항(특허권취득)(자율공시)(항-c-Met 항체 및 이의 용도 (Anti-c-Met antibodies and uses thereof))
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) from Helixmith regarding the acquisition of a patent (Anti-c-Met antibodies). It provides specific details about the patent, the patent holder, the acquisition date, and the intended use. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2021-09-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.